Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 24797 | 251 | 31.9 | 80% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 222 | 19941 | LYMPHANGIOGENESIS//ANGIOGENESIS//ENDOSTATIN |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | LECT2 | Author keyword | 57 | 95% | 8% | 19 |
| 2 | CHONDROMODULIN I | Author keyword | 38 | 76% | 10% | 26 |
| 3 | SHARK CARTILAGE | Author keyword | 23 | 60% | 10% | 25 |
| 4 | LEUKOCYTE CELL DERIVED CHEMOTAXIN 2 | Author keyword | 20 | 100% | 4% | 9 |
| 5 | MOL INTERACT TISSUE ENGN | Address | 19 | 64% | 7% | 18 |
| 6 | AE 941 | Author keyword | 11 | 78% | 3% | 7 |
| 7 | TENOMODULIN | Author keyword | 7 | 46% | 4% | 11 |
| 8 | CHONDROMODULIN II | Author keyword | 6 | 80% | 2% | 4 |
| 9 | LEUKOCYTE CELL DERIVED CHEMOTAXIN 2 LECT2 | Author keyword | 6 | 100% | 2% | 4 |
| 10 | NEOVASTAT | Author keyword | 5 | 63% | 2% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | LECT2 | 57 | 95% | 8% | 19 | Search LECT2 | Search LECT2 |
| 2 | CHONDROMODULIN I | 38 | 76% | 10% | 26 | Search CHONDROMODULIN+I | Search CHONDROMODULIN+I |
| 3 | SHARK CARTILAGE | 23 | 60% | 10% | 25 | Search SHARK+CARTILAGE | Search SHARK+CARTILAGE |
| 4 | LEUKOCYTE CELL DERIVED CHEMOTAXIN 2 | 20 | 100% | 4% | 9 | Search LEUKOCYTE+CELL+DERIVED+CHEMOTAXIN+2 | Search LEUKOCYTE+CELL+DERIVED+CHEMOTAXIN+2 |
| 5 | AE 941 | 11 | 78% | 3% | 7 | Search AE+941 | Search AE+941 |
| 6 | TENOMODULIN | 7 | 46% | 4% | 11 | Search TENOMODULIN | Search TENOMODULIN |
| 7 | CHONDROMODULIN II | 6 | 80% | 2% | 4 | Search CHONDROMODULIN+II | Search CHONDROMODULIN+II |
| 8 | LEUKOCYTE CELL DERIVED CHEMOTAXIN 2 LECT2 | 6 | 100% | 2% | 4 | Search LEUKOCYTE+CELL+DERIVED+CHEMOTAXIN+2+LECT2 | Search LEUKOCYTE+CELL+DERIVED+CHEMOTAXIN+2+LECT2 |
| 9 | NEOVASTAT | 5 | 63% | 2% | 5 | Search NEOVASTAT | Search NEOVASTAT |
| 10 | SHARK CARTILAGE EXTRACT | 3 | 100% | 1% | 3 | Search SHARK+CARTILAGE+EXTRACT | Search SHARK+CARTILAGE+EXTRACT |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LECT2 | 48 | 91% | 8% | 20 |
| 2 | CHONDROMODULIN II | 17 | 100% | 3% | 8 |
| 3 | AE 941 | 15 | 82% | 4% | 9 |
| 4 | CELL DERIVED CHEMOTAXIN 2 | 8 | 75% | 2% | 6 |
| 5 | CARTILAGE SPECIFIC MATRIX | 6 | 80% | 2% | 4 |
| 6 | TUMOR FACTOR CATF | 6 | 100% | 2% | 4 |
| 7 | VASCULARIZED MESENCHYME | 5 | 60% | 2% | 6 |
| 8 | NEOVASTAT AE 941 | 5 | 54% | 3% | 7 |
| 9 | CHONDROMODULIN I | 4 | 20% | 8% | 20 |
| 10 | SHARK CARTILAGE | 4 | 20% | 8% | 19 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Chondromodulin-I and tenomodulin: A new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues | 2005 | 46 | 46 | 39% |
| Hepatic ALECT-2 Amyloidosis Causing Portal Hypertension and Recurrent Variceal Bleeding A Case Report and Review of the Literature | 2014 | 1 | 12 | 50% |
| Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills? | 2000 | 17 | 15 | 67% |
| Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials | 2001 | 79 | 30 | 27% |
| Chondromodulin-I and tenomodulin: The negative control of angiogenesis in connective tissue | 2007 | 17 | 82 | 45% |
| Sharks: A potential source of antiangiogenic factors and tumor treatments | 2002 | 20 | 27 | 52% |
| Shark cartilage as source of antiangiogenic compounds: From basic to clinical research | 2001 | 15 | 23 | 52% |
| ALECT2 amyloidosis: a new type of systemic amyloid highly prevalent in the Hispanic population | 2014 | 0 | 14 | 43% |
| The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells | 2010 | 29 | 156 | 8% |
| Tenomodulin gene and obesity-related phenotypes | 2010 | 3 | 71 | 17% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MOL INTERACT TISSUE ENGN | 19 | 64% | 7.2% | 18 |
| 2 | CELLULAR DIFFERENTIAT | 4 | 25% | 5.2% | 13 |
| 3 | CHEMOTHER Y MYCOSIS | 2 | 67% | 0.8% | 2 |
| 4 | CANCEROL CHARLES BRUNEAU RECH | 1 | 50% | 0.4% | 1 |
| 5 | CENT ILLINOIS CCOP | 1 | 50% | 0.4% | 1 |
| 6 | GHU QUEST | 1 | 50% | 0.4% | 1 |
| 7 | INSERMCNRSU1016UMR 8104 | 1 | 50% | 0.4% | 1 |
| 8 | ABORAT INNOVAT ZHEJIANG MARINE HIGH EFFIC | 0 | 33% | 0.4% | 1 |
| 9 | BIOSCI ENTERPRISE | 0 | 33% | 0.4% | 1 |
| 10 | HUMAN IMMUNOL CANC PROGRAM MED | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000120418 | LUNASIN//CHEMOPREVENTIVE PEPTIDE//CORE HISTONE ACETYLATION |
| 2 | 0.0000102281 | MOUSE HEPATOCARCINOGENESIS//METABOLIC ZONATION//EXPT PATHOL EP |
| 3 | 0.0000095834 | ENDOSTATIN//ANGIOSTATIN//COLLAGEN XVIII |
| 4 | 0.0000092720 | TNP 470//METHIONINE AMINOPEPTIDASE//AGM 1470 |
| 5 | 0.0000092645 | PGLA MICROSPHERES//POLIKLIN REUMATOL//PROTEOGLYCAN SYNTHESIS |
| 6 | 0.0000065399 | SCLERAXIS//ENTHESIS//TENOGENIC DIFFERENTIATION |
| 7 | 0.0000063510 | ALKYLGLYCEROLS//SHARK LIVER OIL//ALKOXYGLYCEROLS |
| 8 | 0.0000051386 | BRANCH SHEMYAKIN BIOORGAN CHEM//HEMATOGENEOUS METASTASIS//PANC02 |
| 9 | 0.0000048216 | ACUTE REJECTION REACTION//TUMOR ANGIOGENESIS//E S 8 |
| 10 | 0.0000047768 | HYPERTHERMIC SENSITIVITY//CELLULAR CHOLESTEROL CONTENT//HIV 1 THERAPY |